Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
A transferrin receptor-targeted antibody transport vehicle improved brain distribution and reduced ARIA-like lesions in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2020) · Nature Methods · doi:10.1038/s41592-019-0686-2 · Cited by 38,430
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
scikit-image: image processing in Python
van der Walt, S., Schönberger, J. L., Nunez-Iglesias, J., Boulogne, F., Warner, J. D., Yager, N., Gouillart, E., & Yu, T. (2014) · PeerJ · doi:10.7717/peerj.453 · Cited by 6,794
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Research works printed but not linked: 2
- T. Bussiere J. Abettan J. Sebalusky S. Hamann A. Silva Amaral D. Walsh D. Bradley E. Plowey “Modeling mechanisms of amyloid-related imaging abnormalities (aria) in transgenic mice treated with anti-aβ immunotherapy and imaged with MRI.” abstract #425 oral presentation at AD/PD 5-9 March 2024 Lisbon Portugal [Preprint] (2024); https://cslide.ctimeetingtech.com/adpd24/attendee/confcal/show/session/14#presentation-abstract-42585247580.
- V. O. Torres M. E. Pizzo D. Chan J. C. Dugas D. Huynh D. Joy E. K. Liang L. Sarrafha I. Becerra R. Chau K. S. Chew J. Chow T. K. Earr N. Khoury K. J. Lechtenberg A. W. Leung H. N. Nguyen E. S. Ojo E. Roche H. Solanoy M. Tong R. K. Tong K. Henne J. W. Lewcock R. J. Watts M. E. Calvert R. G. Thorne Y. J. Y. Zuchero Transferrin receptor-mediated transport at the blood-brain barrier is elevated during early development but maintained across adult aging. BioRxiv 10.1101/2024.11.12.623253 [Preprint] (2024); https://doi.org/10.1101/2024.11.12.623253.10.1101/2024.11.12.623253 · DOI
Cited by
Brain delivery of biotherapeutics via receptor-mediated transcytosis across the blood–brain barrier
Boado, R. J. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00204d · Cited by 23
de Weerd, L., Hummel, S., Müller, S. A., Paris, I., Sandmann, T., Eichholtz, M., Gröger, R., Englert, A. L., Wagner, S., Ha, C., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00878-1 · Cited by 20
“Whether this phenotype could be related to the hTfR KI [48] in these mice is unclear, however another study using 5xFAD; hTfR KI mice did not observe any spontaneous microbleeds without anti-Aβ antibody treatment [44].”
Self-citationAmyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets
Ahmadi, S., Khaledi, S., Ahmadi, K., & Hassanzadeh, K. (2025) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70688 · Cited by 22
“Pizzo et al. [266] recently developed an antibody transport vehicle that targets the transferrin receptor to deliver Aβ antibodies to the brain.”
Serrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 21
Li, J., Guo, L., Cai, W., Mei, J., Liu, J., & Liu, Y. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2645830 · Cited by 22
“Recent studies have employed a ‘Trojan horse’ strategy, utilizing transferrin receptors on cerebrovascular endothelial cells as natural conduits to help antibodies enter the brain parenchyma more precisely and safely (Pizzo et al. 2025).”
Improving Alzheimer’s disease immunotherapy
Xing, M., & Song, W. (2025) · Science · doi:10.1126/science.adz8959 · Cited by 18
Therapeutic targeting of neuroimmune mechanisms in neurodegeneration
Monroe, K. M., Hong, S. Y., Lewcock, J. W., & Yang, A. C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01370-7 · Cited by 16
Self-citationvan Etten, E. S., Mahinrad, S., Grill, J. D., Salloway, S., Atri, A., Cogswell, P. M., Benzinger, T. L. S., Iwatsubo, T., Iadecola, C., Lemere, C. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71361 · Cited by 23
Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system
Lee, H. J., Xie, Y., Greineder, C. F., & Tessier, P. M. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115778 · Cited by 12
Beyond the blood–brain barrier: the fate of transcytosed therapeutics
Baghirov, H. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.006 · Cited by 9
Rehra, L., Erdinger, S., Wagner, L., Baltissen, D., Just, J., König, L., Mühlberg, E., Eisenzapf, T., Kilian, L., Banićević, M., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114374 · Cited by 8
Vega, M., Hansen, H. H., Jensen, C. S., Alexiou, E., Madsen, M. R., Wichern, F., Kristiansen, M. S., Skytte, J. L., Salinas, C. G., Sotty, F., et al. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00737-7 · Cited by 12
Zedde, M., Losa, M., Grisafi, E., Lucia, D. D., Gandoglia, I., Sette, M. D., Pardini, M., Roccatagliata, L., Pascarella, R., & Piazza, F. (2026) · Biomolecules · doi:10.3390/biom16010089 · Cited by 6
“With next-generation monoclonal antibodies optimized for improved blood– brain barrier delivery and reduced ARIA liability, the incidence of drug-induced ARIA is expected to decrease, while spontaneous forms of CAA-ri may correspondingly gain prominence [79,80].”
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 7
Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review
Sumbria, R. K., & Boado, R. J. (2026) · Antibodies · doi:10.3390/antib15020037 · Cited by 5
Transport pathways across the blood-brain barrier for waste clearance and drug delivery
Gröbner, L. S., & Pietrzik, C. U. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00812-7 · Cited by 4
Music enhances lipid nanoparticle brain delivery and mRNA transfection in brain cells
Mora‐Raimundo, P., Gilon, A., Kadosh, H., Richtman, Y., Sela, M., Ackerman, S., Chen, G., Abel, R., Kagan, S., Sharf‐Pauker, N., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114301 · Cited by 4
Du, M., Li, N., Li, T., Zhao, Z., Liu, H., Li, X., Gong, N., Duan, B., Wang, W., Yi, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67207-4 · Cited by 3
“For example, Michelle E. Pizzo et al. developed an anti-A β antibody engineered with a TfR-based domain for brain-targeted antibody delivery and bearing asymmetric Fc effector-reducing mutations, which mitigates ARIA-like lesions in a mouse model of amyloid pathology 44 .”
Zhao, P., Li, S., Liu, Q., Peng, X.-C., Liu, L., Yang, F.-Y., Wang, C., Qian, F., & Tang, F.-R. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1726194 · Cited by 7
Dahlén, A. D., Roshanbin, S., Bucher, N. M., Sehlin, D., & Syvänen, S. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115475 · Cited by 4
“Indeed, when the Fc γ R binding is inhibited using the LALA-PG mutation within the antibody ’ s heavy chain, A β is not cleared from the brain parenchyma to the same extent (Pizzo et al., 2025).”
Amick, J., Bhandarkar, S., Wilcox, D. R., Boloker, S., Lu, Y. D., & Gu, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.10.724157 · Cited by 2
“TfR is a major target in this approach, wherein a TfR-binding antibody is coupled to a therapeutic to be delivered to the brain 35,64,65 .”
Transport vehicle delivers antibodies to the brain
Kingwell, K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/d41573-025-00140-9 · Cited by 1
Choi, E. S., Sahota, S., Burnham, E., Ding, Y., & Shusta, E. V. (2025) · Antibodies · doi:10.3390/antib14040102 · Cited by 1
“While the conventional BBB RMT receptors such as the TfR and the insulin receptor (IR) show promise as brain delivery targets [5,6,8,9,13–19], the search for alternative RMT targets that offer additional benefits such as brain specificity and regiospecificity is also ongoing.”
Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?
Chen, Y. (2026) · Targetome · doi:10.48130/targetome-0026-0004 · Cited by 1
Martínez, R. F., Sánchez-Gallardo, M., & Cintas, P. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118791 · Cited by 1
The role of Annexin A2 in Alzheimer's disease: From cellular functions to therapeutic potential
Shu, D., Fu, C., Liu, Z., & Li, C. (2026) · FEBS Journal · doi:10.1111/febs.70574 · Cited by 1
“Thus, combining ANXA2-based therapies with other AD treatments (e.g. anti-amyloid or anti-inflammatory agents) may synergistically enhance therapeutic efficacy [226,227].”
Bonnar, O., Saadi, F., Sanchez-Mico, M. V., Hanlin, L. H., Eigen, K. A. V., Mumbi, N., Bacskai, B. J., Greenberg, S. M., Holtzman, D. M., & van Veluw, S. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00957-x · Cited by 1
“…future work is needed to fully interrogate the potential impact of surgical preparation on tracking in vivo CAA clearance, through both mechanisms, and considering recent data supporting the notion that peripherally administered antibodies enter the brain first along superficial CSF pathways [31].”
Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease
Brown, C., Robinson, J. L., Das, S. R., McGrew, E., Suh, E. R., Deerlin, V. M. V., Irwin, D. J., Nasrallah, I. M., Mechanic-Hamilton, D. J., Yushkevich, P. A., et al. (2026) · JAMA · doi:10.1001/jama.2026.13058 · Cited by 3
Wang, Q.-Q., Sun, Q.-Q., Guo, Y.-S., Yin, S., & Zhou, J. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00571-3 · Cited by 2
“In 5 × FAD mice, ATVV cisLALA : Aβ nearly eliminated ARIA-like lesions despite achieving higher brain exposure, demonstrating that biodistribution engineering can dissociate efficacy from vascular side effects [488, 489].”
TogoPhosTAC as a delivery-ready platform for targeted protein dephosphorylation
Chen, Y.-Y., Ke, D.-T., Lee, Y., Chen, H., Lin, H.-Y., Yeh, C.-L., Ko, Y.-C., Tu, M., Yu, C., Hu, Z., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76725-8 · Cited by 2
Plowey, E. D., Abettan, J., Chou, P. C., Lye‐Barthel, M., Amaral, A. C. S., Sebalusky, J., Hamann, S., Srinivasan, J., Brown, R. Z., Fang, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702402 · Cited by 1
Self-citationLope‐Piedrafita, S., Serra-Mir, G., Melón, P., Bonaterra‐Pastra, A., Hernández‐Guillamón, M., & Villegas, S. (2025) · Biomolecules · doi:10.3390/biom15111602 · Cited by 1
“The only relevant work we have found where reduction of ARIA-like lesions has been achieved in a new mouse model, the 5xFAD;TfRmu/hu KI, has just been published and it is focused on a very different construct [56,57].”
Expression of matrix metalloproteinases in cerebral amyloid angiopathy-a systematic review
Gu, H., Shi, X., & Zhang, J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1753708
Nelson, K. M., Donzanti, M. J., Mhatre, O., & Gleghorn, J. P. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-102723-021307 · Cited by 3
Transport vehicle–mediated TREM2 PET maps myeloid cells in the glioblastoma microenvironmentPreprint
Brendel, M., Bartos, L. M., Feng, R., Mueller, K., Koessinger, A. L., Teske, N. C., Greve, T., Kirchleitner, S. V., Blobner, J., Nikolaishvili, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8627080/v1
Self-citationPikus, P., Healey, G. S., Xia, E., Shautidze, G., Siddapureddy, N., Lee, Y., Albanese, C., Rodriguez, O. C., Turner, R. S., & Rebeck, G. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.09.704876 · Cited by 1
Beyond the magic bullet: Programming delivery systems to overcome the antibody specificity paradox
Ma, Y., Zhou, Y., Xu, C., Gao, P., Gao, H., Luo, L., & Gao, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114744 · Cited by 1
Astrocytes engineered to fight Alzheimer’s plaques
Boles, J. S., & Gate, D. (2026) · Science · doi:10.1126/science.aef8451
Physiological strategies for brain delivery
Carter, D. A. G. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.02.007
Lysosome-targeting protein degradation: from mechanistic insights to strategic design
YaLi, W. U., Zhao, H., FaHui, Z. H. U., Jiang, Y., Chen, M., Ba, M., Ang, L. I., & He, W. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0410
Liu, J., Jing, L., Fan, Y., Liu, C., Cao, J., Ma, H., Hou, Y., Gao, S., & Wang, P. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08098-x
Moëlo, C., Kronqvist, N., & Johansson, J. (2026) · Advanced Biology · doi:10.1002/adbi.202500721 · Cited by 1
Dinamarca, M. C., Ševarika, B., & McNeil, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050619 · Cited by 1
“In contrast, transferrin-mediated transcytosis across the BBB is a well-characterized and widely studied mechanism for CNS drug delivery [8–10,13 ,35 ].”
InfluentialBrain shuttle target expression levels vary by individual, not by brain region, disease, age, or sexPreprint
Santa-Maria, A. R., Shahriar, S., Chandrasekhar, V., Luteijn, E., Horber, R., Hornstein, S., Tkachev, S. L., Levy, T. M., Gregoretti, I. V., Simpson, C. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.21.726908
Fritz, N., Johannesson, M., Eriksson, F., Osswald, G., Lannfelt, L., Möller, C., & Söderberg, L. (2026) · Neuroscience Letters · doi:10.1016/j.neulet.2026.138645
Labant, M. (2026) · Genetic Engineering & Biotechnology News · doi:10.1177/1935472x261451933
Wik, E., Dahlén, A. D., Julku, U. H., Xiong, M., Michno, W., Syvänen, S., & Sehlin, D. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00949
“As a result, only approximately 0.1% of the administered dose reaches the brain parenchyma, but is then confined to certain compartments, such as central periventricular areas or superficial leptomeningeal tissue [8,9,11 – 13].”
InfluentialChimeric antigen receptor‐macrophages: A new paradigm for cell therapy
Wang, H., Li, Y., Shi, Y., Zhou, Y., & Zheng, G. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70157 · Cited by 1
Advances in the Diagnosis and Management of Alzheimer’s Disease
Joshi, P., Tsai, P., Alix, A., & Gopalakrishna, G. (2026) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2026.05.004
Next generation medicines: Emerging approaches to drug ‘difficult to drug’ targets
Owen, D. R., Chaparro‐Riggers, J. F., Levengood, M. R., & Tadin‐Strapps, M. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100016
Ding, Z., Gibson, K. A., Nascari, D. G., Tallant, L., Bouchal, S. M., Dickson, D. W., & Fryer, J. D. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70269 · Cited by 1
“13 However, the clinical translation of these engineered formats also requires a broader understanding of their impact on the disease’s overall progression.”
Is amyloid beta peptide a driver of inflammaging?
Kechko, O. I., Moskalev, A. A., Franceschi, C., Mitkevich, V. A., & Makarov, A. А. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103280 · Cited by 1
Tau-targeting pharmacological strategies in neurodegenerative disease
Zheng, H., & Zheng, J. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.07.008
Mitophagy in neuronal health and disease: from mechanisms to neurodegeneration
Basak, B., Riley, J. F., Nataraj, N. M., & Holzbaur, E. L. F. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199847 · Cited by 1
Alzheimer’s Disease: Progress in Biomarkers, Diagnostics and Therapies
Wilson, E. N., Sommer, B., Scheltens, P., & Nikolich, K. (2026) · Springer eBooks · doi:10.1007/978-3-032-31497-0_8
Antibody-Based Biologics for CNS Disorders
Hui, E. K., & Boado, R. J. (2026) · Antibodies · doi:10.3390/antib15050086
“AD biomarkers, amyloid and total and phosphorylated Tau, were also reduced in CSF. Trontinemab showed a safety profile, with ARIA occurring in <5% of patients, and no new cases have been reported [129].”
Metadata
- Authors
- Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., Roche, E., Chan, D., Dugas, J. C., Gadkar, K., Hamann, S., Meisner, R., Sebalusky, J., Silva Amaral, A. C., Becerra, I., Chau, R., Chow, J., Clemens, A. J., Dennis, M. S., Duque, J., Fusaro, L., Getz, J. A., Kariolis, M. S., Kim, D. J., Lechtenberg, K. J., Leung, A. W.-S., Moshkforoush, A., Nguyen, H. N., Ojo, E. S., Thomsen, E. R., Torres, V. O., Sanchez, P. E., Shan, L., Silverman, A. P., Sweeney, Z. K., Solanoy, H., Tong, R., Calvert, M. E., Watts, R. J., Thorne, R. G., Weinreb, P. H., Walsh, D. M., Lewcock, J. W., Bussiere, T., & Zuchero, Y. J. Y.
- Affiliations
- Denali Therapeutics (United States) (US)
- Biogen (United States) (US)
- Biogen, Cambridge, MA, USA.
- Denali Therapeutics, Inc., South San Francisco, CA, USA.
- University of Minnesota (US)
- Corresponding author
- Zuchero, Y. Joy Yu
- ORCID
- Pizzo, Michelle E.
- Plowey, Edward D.
- Abettan, Jordan
- DeVos, Sarah L.
- Discenza, Claire B.
- Earr, Timothy
- Joy, David
- Chan, Darren
- Dugas, Jason C.
- Gadkar, Kapil
- Hamann, Stefan
- Meisner, René
- Sebalusky, Jennifer
- Silva Amaral, Ana Claudia
- Chau, Roni
- Chow, Johann
- Dennis, Mark S.
- Duque, Joseph
- Fusaro, Laura
- Getz, Jennifer A.
- Kariolis, Mihalis S.
- Kim, Do Jin
- Lechtenberg, Kendra J.
- Leung, Amy Wing-Sze
- Moshkforoush, Arash
- Nguyen, Hoang N.
- Thomsen, Elliot R.
- Torres, Vanessa O.
- Sanchez, Pascal E.
- Shan, Lu
- Silverman, Adam P.
- Sweeney, Zachary K.
- Solanoy, Hilda
- Tong, Raymond
- Calvert, Meredith E.
- Watts, Ryan J.
- Thorne, Robert G.
- Weinreb, Paul H.
- Walsh, Dominic M.
- Lewcock, Joseph W.
- Bussiere, Thierry
- Zuchero, Y. Joy Yu
- Venue
- Science
- Published
- 2025-08-07
- Volume
- 389
- Issue
- 6760
- Pages
- eads3204-eads3204
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4413045841
- Cited by
- 63
- References
- 73
- Citations by year
- 2026: 49 · 2025: 14
- FWCI
- 40.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- amyloid-related imaging abnormalities, anti-amyloid therapy, transferrin receptor, amyloid-beta immunotherapy, brain drug delivery, blood-brain barrier, Alzheimer's disease, vascular inflammation, amyloid plaques, antibody biodistribution
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Monoclonal, Blood-Brain Barrier, Brain, Humans, Immunoglobulin Fc Fragments, Magnetic Resonance Imaging, Mutation, Receptors, Transferrin, Tissue Distribution, Amyloid beta-Peptides, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.